Japan Found the Sleep Switch. Why Has the West Been Slow to Profit?

The Discovery That Changed Everything — Until It Didn’t

Twenty-eight years ago, Masashi Yanagisawa was working at the University of Texas, Dallas, injecting rat brains with newly discovered molecules. He found something remarkable. He called it “orexin,” borrowing from the Greek word for appetite, because early tests showed the substance made rats eat voraciously.

But then the mouse experiments began to show something else entirely. When researchers removed the orexin gene from mice, the animals didn’t just lose interest in food. They collapsed into sudden sleep attacks. Narcolepsy, a devastating neurological disorder characterized by uncontrollable daytime sleepiness, revealed its molecular cause: the absence of orexin-producing neurons in the hypothalamus.

Yesterday, the scientific world caught up. Four Japanese scientists, led by Yanagisawa now at Tsukuba University, received the Lasker Award — often considered a precursor to the Nobel Prize — for this discovery. In an interview with ANN, Yanagisawa called it a landmark moment for a field that had long been sidelined.

“Sleep research has never received a truly prestigious academic award before this,” he said. “I think this field has been neglected within basic research.”

The recognition is overdue. The commercial implications, however, remain largely unexploited outside Japan.

A $100 Billion Market Left Sitting

The global sleep disorder market is projected to exceed $100 billion by 2026. Narcolepsy alone affects an estimated 2 million people worldwide, with many more suffering from insomnia, sleep apnea, and hypersomnia. The orexin pathway has emerged as the most promising target for next-generation treatments — particularly for disorders that respond poorly to existing therapies.

Western pharmaceutical companies, however, have been notably cautious. While Japanese firms like Eisai and Astellas have accelerated orexin-targeting drug development, American and European competitors have lagged. The reasons are not purely scientific. They reflect structural gaps in how sleep research is funded, how clinical trials are designed, and how regulatory pathways prioritize sleep disorders versus conditions with louder patient advocacy.

Yanagisawa noted the disconnect between scientific understanding and public practice. “There is a massive gap between what specialists know and what the general public believes about sleep,” he said. “We need to close that gap.”

That gap is commercial, too. Sleeping pills based on GABA receptors — the current standard for insomnia — have significant side effects including dependency and cognitive impairment. Orexin antagonists offer a fundamentally different mechanism: they don’t sedate the brain. They simply turn off the wakefulness signal. The first orexin antagonist, suvorexant, received FDA approval in 2014 but has faced pricing and market-access challenges that have limited its adoption.

Japanese researchers identified the mechanism. Japanese companies are now developing the treatments. Western companies are still catching up.

Who Wins, Who Loses

The Lasker Award changes the calculus. It signals to investors and regulators that sleep science is no longer fringe research. It validates decades of work by scientists who were told their focus on sleep was less rigorous than work on cancer or neurodegeneration.

For patients with narcolepsy and other sleep-wake disorders, the implications are immediate. Orexin-based therapies could transform treatment from symptomatic management to disease-modifying intervention. Early clinical data suggests improved daytime alertness with fewer side effects than current options. The question is not whether these drugs will reach market but how quickly.

Western pharmaceutical companies stand to lose if they continue to underinvest. Japanese firms that moved first could secure dominant market positions in a segment that major U.S. and European players previously dismissed. The orexin pathway is a gateway technology — patents filed in Japan have broad international reach, and the foundational research was published in journals that Western researchers can read but cannot easily replicate without the original discovery context.

Regulators also face a choice. The FDA and EMA have approved orexin-targeting drugs, but approval timelines remain longer than for many other therapeutic areas. Insurance reimbursement structures continue to disadvantage newer mechanisms of action. The Lasker Award may pressure these institutions to accelerate evaluation — or it may simply become another prestige marker that changes marketing decks without altering market access.

What Happens Next

Yanagisawa’s comments during the press conference revealed something surprising. When asked whether he slept well after learning he had won the Lasker Award, he responded matter-of-factly: “I slept normally. You have to sleep. If you don’t, your brain performance drops, and you need to be aware of that. If Japanese people become aware of this, sleep deprivation could be solved.”

The irony is deliberate. The man who discovered the molecule regulating wakefulness is urging the public to prioritize sleep — not as a luxury but as a biological necessity. His observation that Japanese sleep habits are deteriorating despite growing scientific understanding underscores the paradox: the research community knows more than ever, but public behavior has not kept pace.

The commercial race will intensify. Multiple orexin antagonists are in late-stage trials across Asia and North America. Orexin agonists — designed to treat hypersomnia rather than insomnia — represent an even larger opportunity. Companies that fail to build pipelines around this target risk ceding ground to Japanese and Korean rivals who recognized the value early.

For Western pharma, the lesson is not that sleep research is suddenly valuable. The lesson is that they missed the signal for two decades. The Lasker Award is recognition, not retaliation. But in a $100 billion market, recognition translates to revenue — and revenue determines who leads the next decade of sleep medicine.

Yanagisawa’s career trajectory — from Texas to Tsukuba, from appetite research to sleep discovery, from neglect to the Lasker stage — illustrates a broader pattern in global science. The most important discoveries do not always originate in the institutions with the most visibility. Sometimes they emerge from laboratories where researchers were simply curious enough to follow the data, even when it led somewhere unexpected.

The orexin story is no longer just about sleep. It is about who controls the next wave of neurological therapeutics, and who gets left behind.